Rilzabrutinib approved for the treatment of patients with immune thrombocytopenia.
It is an oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of patients with immune thrombocytopenia (ITP).
Rilzabrutinib is an oral, reversible covalent, BTK inhibitor for the treatment of immune mediated diseases.
BTK patticpates in innate and adaptive immune responses and is a signaling molecule found in immune mediated diseases.
The drug has the ability to block inflammatory immune cells, eliminate autoantibody destructive signalling, and prevent new autoantibody production without depleting B cells.
It has the potential to target the underlying disease pathogenesis and has not been shown to alter platelet aggregation.